MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

FibroGen Inc

Open

SectorGezondheidszorg

11.79 2.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.23

Max

12

Belangrijke statistieken

By Trading Economics

Inkomsten

-12M

-7.6M

Verkoop

-1.4M

1.3M

EPS

-1.88

Winstmarge

-564.021

Werknemers

225

EBITDA

2.6M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+257.74% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

16M

50M

Vorige openingsprijs

9.18

Vorige sluitingsprijs

11.79

Nieuwssentiment

By Acuity

76%

24%

343 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

FibroGen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Acquisities, Fusies, Overnames

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Acquisities, Fusies, Overnames

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Peer Vergelijking

Prijswijziging

FibroGen Inc Prognose

Koersdoel

By TipRanks

257.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43 USD  257.74%

Hoogste 43 USD

Laagste 43 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor FibroGen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

0.306 / 0.33939Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

343 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

help-icon Live chat